Stock comparison
Genmab A/S
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 70B | HAE |
| Benjamin Graham | 64C | 85A | HAE |
| Philip Fisher | 48D | 60C | HAE |
| Peter Lynch | 25F | 54C | HAE |
| Joel Greenblatt | 76B | 31F | GMAB |
| Charlie Munger | 68C | 54D | GMAB |
| Terry Smith | 71C | 55D | GMAB |
Side-by-side metrics
| Metric | GMAB | HAE |
|---|---|---|
| Market cap | $16.5B | $2.98B |
| P/E (TTM) | 6.2x | 24.8x |
| EV/EBIT | 12.0x | 14.1x |
| ROIC (TTM) | 43.78% | 8.37% |
| Gross margin | 93.88% | 55.74% |
| Net margin | 18.23% | 7.29% |
| Revenue CAGR 5y | -18.45% | 7.65% |
| EPS CAGR 5y | -23.48% | 24.62% |
| Debt / Equity | 0.1x | 1.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 1.5x+95%
- Market cap$16.5Bvs $2.98B+82%
- ROIC (TTM)43.78%vs 8.37%+81%
- P/E (TTM)6.2xvs 24.8x+75%
HAE leads on
- EPS CAGR 5y24.62%vs -23.48%+195%
- Revenue CAGR 5y7.65%vs -18.45%+141%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.